Can Alzheimer’s disease be slowed by flickering lights and sound?That is the question that drives Annabelle Singer, an associate professor and biomedical engineer at Georgia Institute of Technology and Emory University. https://t.co/AVMVSvRMRT https://t.co/NLWI2VPoxP ...

Divergent diagnostic criteria for Alzheimer’s disease is raising concerns that some patients are being misdiagnosed and unnecessarily treated. 🔗 https://t.co/mMeJM8QAes https://t.co/jvNqpxjv0L ...

Your Health: Divergent diagnostic criteria for Alzheimer’s disease is raising concerns that some patients are being misdiagnosed and unnecessarily treated https://t.co/hlArsx5Tq6 ...

Drug Development - Novo Nordisk's oral Ozempic for Alzheimer's showed biological response in some areas despite failed trials [1] - The company is considering further research on the pill version of Ozempic for Alzheimer's [1] Clinical Trial Outcomes - Alzheimer's patients in the trials did not experience cognitive improvement [1]

Drug Development - Danish pharma giant (诺和诺德) 正在关注其减肥药物的关键成分 semaglutide 的试验结果，该结果显示其在减缓阿尔茨海默病进展方面无效 [1]

Clinical Trial Results - Novo Nordisk shares experienced a sharp decline following the announcement that a pill containing the active ingredient found in Ozempic and Wegovy failed to demonstrate efficacy in slowing Alzheimer's disease progression in two late-stage clinical trials [1] Pharmaceutical Industry Implications - The unsuccessful trial results highlight the challenges and risks associated with drug development in the treatment of Alzheimer's disease [1]

Health & Wellness - Sleep's potential role in preventing Alzheimer's disease onset and progression is being explored [1] Research Focus - Bloomberg Prognosis is investigating the link between sleep and Alzheimer's disease [1]

Drug Development - Roche Holding 计划测试一种实验性药物，以预防高危人群出现阿尔茨海默病症状 [1] - 该计划代表了 Roche 在药物开发领域（尤其是在容易失败的领域）的最新投资 [1]

Regulatory Approval - Lilly's Alzheimer's disease drug Kisunla receives backing from EU regulators for use in a specific patient group [1]

Funding & Investment - Illimis Therapeutics secured 58 billion won (approximately $42 million) in funding [1] - The funding aims to support research into Alzheimer's disease treatments [1] - The funding will also facilitate expansion into immune diseases [1] Company Focus - Illimis Therapeutics is based in Seoul [1] - The company is focused on developing treatments for Alzheimer's disease [1] - The company is expanding its research focus to include immune diseases [1]